REG - PureTech Health PLC - Transaction in Own Shares

Puretech HealthAnnouncement

25/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240125:nRSY8282Aa&default-theme=true

RNS Number : 8282A  PureTech Health PLC  25 January 2024

25 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.

 

 Date of purchase:                              24 January 2024

 Number of ordinary shares purchased:           35,192

 Highest price paid per share:                  198.00p

 Lowest price paid per share:                   192.80p

 Volume weighted average price paid per share:  195.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 18,884,863 ordinary
shares in treasury and has 270,583,296 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 270,583,296 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X, formerly known as
Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

 Transaction Date  Transaction Time  Volume  Price (GBp)  Platform  Transaction Reference Number
 24/01/2024        08:29:27          815     192.8        XLON      00386861372TRLO0.1.1
 24/01/2024        08:29:44          315     192.8        CHIX      00386861432TRLO0.1.1
 24/01/2024        08:29:44          213     192.8        CHIX      00386861433TRLO0.1.1
 24/01/2024        08:29:59          815     192.8        XLON      00386861483TRLO0.1.1
 24/01/2024        08:30:43          916     192.8        XLON      00386861719TRLO0.1.1
 24/01/2024        08:31:31          622     192.8        XLON      00386862022TRLO0.1.1
 24/01/2024        08:34:33          515     192.8        XLON      00386862779TRLO0.1.1
 24/01/2024        08:34:33          13      192.8        XLON      00386862780TRLO0.1.1
 24/01/2024        08:39:41          528     192.8        XLON      00386864131TRLO0.1.1
 24/01/2024        08:44:47          528     192.8        XLON      00386865524TRLO0.1.1
 24/01/2024        09:32:54          6336    195          XLON      00386876245TRLO0.1.1
 24/01/2024        09:34:07          173     195          CHIX      00386876729TRLO0.1.1
 24/01/2024        09:34:36          96      195          CHIX      00386876791TRLO0.1.1
 24/01/2024        09:37:02          2112    195.4        XLON      00386877399TRLO0.1.1
 24/01/2024        09:37:08          528     194.8        BATE      00386877491TRLO0.1.1
 24/01/2024        09:37:08          528     194.8        CHIX      00386877492TRLO0.1.1
 24/01/2024        09:37:08          283     194.8        AQXE      00386877493TRLO0.1.1
 24/01/2024        09:58:58          528     197          XLON      00386882071TRLO0.1.1
 24/01/2024        10:00:28          193     197          CHIX      00386882619TRLO0.1.1
 24/01/2024        10:00:28          291     197.2        CHIX      00386882620TRLO0.1.1
 24/01/2024        10:08:52          283     196.8        AQXE      00386884053TRLO0.1.1
 24/01/2024        10:08:52          1584    196.8        XLON      00386884055TRLO0.1.1
 24/01/2024        10:08:52          283     196.8        AQXE      00386884054TRLO0.1.1
 24/01/2024        10:08:52          342     196.6        TRQX      00386884056TRLO0.1.1
 24/01/2024        10:16:28          1056    196.6        XLON      00386885232TRLO0.1.1
 24/01/2024        10:16:28          481     196.6        XLON      00386885233TRLO0.1.1
 24/01/2024        10:39:12          35      196.4        CHIX      00386889783TRLO0.1.1
 24/01/2024        10:39:12          493     196.4        CHIX      00386889784TRLO0.1.1
 24/01/2024        10:39:12          388     196.4        CHIX      00386889785TRLO0.1.1
 24/01/2024        10:39:12          528     196.4        XLON      00386889787TRLO0.1.1
 24/01/2024        10:39:12          575     196.4        XLON      00386889786TRLO0.1.1
 24/01/2024        10:39:12          231     196.4        XLON      00386889788TRLO0.1.1
 24/01/2024        10:39:12          148     196.4        XLON      00386889789TRLO0.1.1
 24/01/2024        10:39:12          176     196.4        XLON      00386889790TRLO0.1.1
 24/01/2024        10:39:13          35      196          BATE      00386889793TRLO0.1.1
 24/01/2024        11:13:47          2112    196.4        XLON      00386895560TRLO0.1.1
 24/01/2024        11:14:55          119     196.2        CHIX      00386895706TRLO0.1.1
 24/01/2024        11:34:12          579     196.4        CHIX      00386898389TRLO0.1.1
 24/01/2024        11:34:12          528     196.4        BATE      00386898390TRLO0.1.1
 24/01/2024        11:34:12          2085    196.4        XLON      00386898391TRLO0.1.1
 24/01/2024        11:48:28          528     196.8        XLON      00386901072TRLO0.1.1
 24/01/2024        11:50:46          409     196.2        BATE      00386901394TRLO0.1.1
 24/01/2024        11:50:46          2112    196.4        XLON      00386901395TRLO0.1.1
 24/01/2024        12:20:02          528     197          XLON      00386906123TRLO0.1.1
 24/01/2024        14:44:34          283     198          AQXE      00386943011TRLO0.1.1
 24/01/2024        14:44:34          287     198          CHIX      00386943012TRLO0.1.1
 24/01/2024        14:46:50          500     198          XLON      00386945228TRLO0.1.1
 24/01/2024        14:46:50          154     198          CHIX      00386945227TRLO0.1.1
 24/01/2024        14:46:50          52      198          TRQX      00386945229TRLO0.1.1
 24/01/2024        14:46:50          28      198          XLON      00386945230TRLO0.1.1
 24/01/2024        14:46:50          199     198          TRQX      00386945231TRLO0.1.1
 24/01/2024        14:46:50          119     198          TRQX      00386945232TRLO0.1.1
 24/01/2024        14:46:50          472     198          XLON      00386945233TRLO0.1.1
 24/01/2024        14:46:50          56      198          XLON      00386945234TRLO0.1.1
 24/01/2024        14:46:50          528     198          XLON      00386945235TRLO0.1.1
 24/01/2024        14:46:50          528     198          XLON      00386945236TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFLFLTLIISFIS